Phase II clinical trial to examine Allogeneic Fibroblast therapy for Epidermolysis Bullosa
Lead Participant:
INTERCYTEX LIMITED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| INTERCYTEX LIMITED | £271,022 | £ 162,613 |
Participant |
||
| KING'S COLLEGE LONDON BUSINESS LIMITED | £111,342 | £ 111,342 |
People |
ORCID iD |